MAIA Biotechnology, Inc. shared new efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer, reporting that 19 patients had over 12 months of survival follow-up, with an interim median survival of 11.5 months in third-line treatment.